TABLE 1.

LPV and ritonavir PK parameters and concentrations in serum after initiation of 400 and 100 mg, respectively, intrapartum^a

Drug and parameter	Within 72 h postpartum (n = 16)	At day 30 postpartum (n = 14)	Within-subject geometric mean 72-h/day 30 ratio (90% CI)f
LPV
AUC0-12 (μg·h/ml)	99.7 (66.3-180.5)
Cmax (μg/ml)	11.17 (8.01-17.52)
Tmax (h)	3.9 (1.9-4.0)
Cpredose (μg/ml)	6.08 (2.34-13.64)	9.17 (5.28-14.97)	0.66 (0.53-0.81)b
C2 h (μg/ml)	10.50 (5.87-17.53)	11.72 (7.42-19.88)	0.85 (0.70-1.04)
C4 h (μg/ml)	10.78 (8.01-16.72)	12.96 (8.78-21.37)	0.81 (0.71-0.94)c
C12 h (μg/ml)	5.18 (1.68-12.54)
Ritonavir
AUC0-12 (μg·h/ml)	4.27 (1.54-7.89)
Cmax (μg/ml)	0.60 (0.33-1.33)
Tmax (h)	3.9 (1.9-4.0)
Cpredose (μg/ml)	0.16 (<0.05-1.33)	0.29 (0.09-0.66)	0.54 (0.39-0.74)d
C2 h (μg/ml)	0.45 (0.14-1.33)	0.61 (0.15-1.45)	0.76 (0.60-0.98)e
C4 h (μg/ml)	0.58 (0.18-1.33)	0.81 (0.21-3.11)	0.68 (0.50-0.93)e
C12 h (μg/ml)	0.10 (<0.05-0.26)

^aReported values are medians and ranges. C_predose, C_{2 h}, C_{4 h}, and C_{12 h} are the predose and 2-, 4-, and 12-h postdose drug concentrations in serum, respectively.

^bGeometric mean significantly lower (P = 0.009, Wilcoxon signed-rank test).

^cGeometric mean significantly lower (P = 0.048, Wilcoxon signed-rank test).

^dGeometric mean significantly lower (P = 0.038, Wilcoxon signed-rank test).

^eGeometric mean significantly lower (P = 0.030, Wilcoxon signed-rank test).

^fCI, confidence interval.